




# Autoimmune Conditions

**\*\*It is preferred that all patients with autoimmune disorders discuss the vaccine with their HCP prior to presenting for immunization.**

**NOTE:** AstraZeneca/COVISHIELD COVID-19 Vaccine: clients with a previous history of thrombosis associated with lupus anticoagulant (thrombotic anti-phospholipid syndrome) should not receive this vaccine due to very rare reports of a combination of blood clots and low levels of blood platelets following immunization.





# Autoimmune Conditions

**What is the optimal timing for COVID-19 vaccination of Multiple Sclerosis patients receiving treatment?**

\*\*It is preferred that all patients with autoimmune disorders discuss the vaccine with their HCP prior to presenting for immunization.

Treatment	Recommendation
<ul style="list-style-type: none"> <li>Glatiramer acetate (any type), interferon-beta (any type), teriflunomide, dimethylfumarate (or any type of fumaric acid ester), and natalizumab.</li> <li>Patients who previously received cladribine, alemtuzumab, mitoxantrone, cyclophosphamide or a hematopoietic stem cell transplant, and have reconstituted their lymphocytes (generally <math>\geq 0.5</math>-<math>0.8 \times 10^9</math> cells/L).</li> </ul>	No alteration to vaccination timing. Patients on these treatments need and are expected to have little, if any, reduction in vaccine effectiveness
<ul style="list-style-type: none"> <li>Fingolimod, ozanimod, and siponimod.</li> </ul>	No alteration in vaccine timing. Patients on these treatments may have a modest decrease in vaccine effectiveness.
<ul style="list-style-type: none"> <li>Ocrelizumab, rituximab*, and ofatumumab</li> </ul>	Delay the first dose until 4 weeks after vaccine completion. If treatment has already started, the vaccine should be given at least 4 weeks before and 4 weeks after a treatment dose.
<ul style="list-style-type: none"> <li>Cladribine, alemtuzumab, mitoxantrone, cyclophosphamide, and hematopoietic stem cell transplant.</li> </ul>	<b><u>Delay vaccination until appropriate immune reconstitution has taken place</u></b> (which the patient needs to discuss with their physician/specialist):

\*For patients with other auto-immune disorders receiving ongoing treatment with RITUXIMAB - delay vaccination until minimum of 4 weeks after the last dose of Rituximab, unless otherwise directed by their Health Care Provider.

Common Auto Immune Conditions* <sup>1</sup> (This is not an exhaustive list)			
Addison's	Erythema nodosum	Lupus	Psoriatic arthritis
Alopecia areata	Fibromyalgia	Meniere's disease	Raynaud's syndrome
Amyloidosis	Graves' disease	Multiple Sclerosis	Restless legs syndrome
Ankylosing spondylitis	Guillain-Barre syndrome	Myasthenia gravis	Rheumatoid arthritis
Celiac Disease	Hashimoto's thyroiditis	Neutropenia	Sarcoidosis
Crohn's Disease	Hemolytic anemia	Henoch-Schonlein purpura	Scleroderma
Diabetes Type 1	Juvenile arthritis	Optic Neuritis	Thrombocytopenic purpura
Endometriosis	Kawasaki disease	Psoriasis	Ulcerative Colitis

<sup>1</sup>list obtained American Autoimmune Related Disease Ltd. <https://www.aarda.org/diseaselist/>